蘑菇AV

Digital ad spend by the US travel industry will grow by 14.3% this year for a total of $6.79 billion, according to our forecast.

Search and advertising come under fire as the CMA takes a proactive approach to regulation while the US DOJ focuses on punitive remedies.

US social network ad spend will reach $82.89 billion this year, according to our October 2023 forecast.

Shake Shack is also building excitement and awareness around its brand by boosting its advertising spend and introducing limited-time offerings like a black truffle burger. Those efforts aim to ensure Shake Shack preserves its status as a premium brand.

TikTok鈥檚 top brands pulled back spending after ban signing: Ad spend growth slowed in the month after the ban was signed, and major retailers like Target reduced spend.

The US is the overwhelming center of gravity for all things advertising鈥攁nd it will remain that way, even though 2023 will see a slight share drop for the country across various metrics. By the end of next year, the US shares of total and digital ad spending will increase once again.

RFK Jr.鈥檚 pharmaceutical ad ban could affect $22 billion in ad spending: A business-friendly Trump administration could hamper RFK鈥檚 plans to cut D2C advertising.

But in-store retail media spend is powering digital OOH spend, making up 15% of the channel鈥檚 ad dollars this year, per our November 2024 forecast.

Follow us on Instagram. Episode Transcript:. Max:. Publishers have been able to say with a straight face that they do deliver immense value to their audiences, but it's been really hard to kind of tell that story in a consistently convincing way to advertisers. Marcus:. Hey, gang. It's Friday, January 10th. Max. Geoff and listeners, welcome to Behind the Numbers, an eMarketer podcast. I'm Marcus.

The US is one of only two countries (New Zealand being the other) where D2C pharma advertising is completely legal. Kennedy believes lax pharma ad rules have led to an overreliance on prescription medications among Americans. He also believes pharma companies account for too much of TV ad spending, leaving media companies less likely to cover the sector critically.